Mundhenke Christoph, Meyer Kristy, Drew Sally, Friedl Andreas
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin 52792-8550, USA.
Am J Pathol. 2002 Jan;160(1):185-94. doi: 10.1016/S0002-9440(10)64362-3.
Binding of fibroblast growth factors (FGFs) to their tyrosine kinase-signaling receptors (FGFRs) requires heparan sulfate (HS). HS proteoglycans (HSPGs) determine mitogenic responses of breast carcinoma cells to FGF-2 in vitro. For this study, we examined the role of HSPGs as modulators of FGF-2 binding to FGFR-1 in situ and in vitro. During stepwise reconstitution of the FGF-2/HSPG/FGFR-1 complex in situ, we identified an elevated ability of breast carcinoma cell HSPGs to promote receptor complex formation compared to normal breast epithelium. HSPGs isolated from the MCF-7 breast-carcinoma cell line were then fractionated according to their ability to assemble the FGF-2 receptor complex. All MCF-7 HSPGs are decorated with HS chains similarly capable of promoting FGF-2 receptor complex formation. In this in vitro model, syndecan-1 and syndecan-4 are the cell surface HSPGs contributing most to the complex formation. Relative expression levels of these syndecans in human breast carcinoma tissues correlate well with receptor complex formation in situ, indicating that in breast carcinomas, core protein levels determine FGF-2 receptor complex formation. However, variances in syndecan expression levels do not explain the difference in FGF-2 receptor complex formation between normal and malignant epithelial cells, suggesting that alterations in HS structure occur during malignant transformation.
成纤维细胞生长因子(FGFs)与其酪氨酸激酶信号受体(FGFRs)的结合需要硫酸乙酰肝素(HS)。硫酸乙酰肝素蛋白聚糖(HSPGs)决定了乳腺癌细胞在体外对FGF-2的促有丝分裂反应。在本研究中,我们检测了HSPGs作为FGF-2与FGFR-1原位及体外结合调节剂的作用。在原位逐步重建FGF-2/HSPG/FGFR-1复合物的过程中,我们发现与正常乳腺上皮相比,乳腺癌细胞HSPGs促进受体复合物形成的能力有所提高。然后,根据从MCF-7乳腺癌细胞系中分离出的HSPGs组装FGF-2受体复合物的能力进行分级。所有MCF-7 HSPGs都带有硫酸乙酰肝素链,同样能够促进FGF-2受体复合物的形成。在这个体外模型中,Syndecan-1和Syndecan-4是对复合物形成贡献最大的细胞表面HSPGs。这些Syndecan在人乳腺癌组织中的相对表达水平与原位受体复合物的形成密切相关,表明在乳腺癌中,核心蛋白水平决定了FGF-2受体复合物的形成。然而,Syndecan表达水平的差异并不能解释正常上皮细胞和恶性上皮细胞之间FGF-2受体复合物形成的差异,这表明在恶性转化过程中硫酸乙酰肝素结构发生了改变。